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Abstract
Introduction Sensitive and specific assessment of the
hepatic graft metabolism after liver transplantation (LTX)
is essential for early detection of postoperative dysfunction
implying the need for consecutive therapeutic
interventions.
Objectives Here, we assessed circulating liver metabolites
of the cholesterol pathway, amino acids and acylcarnitines
and evaluated their predictive value on early allograft
dysfunction (EAD) and clinical outcome in the context of
LTX.
Methods The metabolites were quantified in the plasma of
40 liver graft recipients one day pre- and 10 days post-LTX
by liquid chromatography/tandem mass spectrometry (LC–
MS/MS). Plant sterols as well as cholesterol and its pre-
cursors were determined in the free and esterified form;
lanosterol in the free form only. Metabolites and esterifi-
cation ratios were compared to the model for early allograft
function scoring (MEAF) which is calculated at day 3 post-
LTX from routine parameters defining EAD.
Results The hepatic esterification ratio of all sterols, but
not amino acids and acylcarnitine concentrations, showed
substantial metabolic disturbances post-LTX and correlated
to the MEAF. In ROC analysis, the low esterification ratio
of b-sitosterol and stigmasterol from day 1 and of the other
sterols from day 3 were predictive for a high MEAF, i.e.
EAD. Additionally, the ratio of esterified b-sitosterol and
free lanosterol were predictive for all days and the esteri-
fication ratio of the other sterols at day 3 or 4 post-LTX for
3-month mortality.
Conclusion Low ratios of circulating esterified sterols are
associated with a high risk of EAD and impaired clinical
outcome in the early postoperative phase following LTX.
Keywords Liver transplantation  Sterol metabolism 
MEAF
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1 Introduction
Liver transplantation (LTX) is a life-saving treatment
option for patients suffering from a variety of liver diseases
including acute and chronic liver failure, hepatocellular
carcinoma and fulminant hepatitis. Over the past 50 years,
significant improvements in immunosuppression, surgical
technique and postoperative management of liver allograft
recipients have paved the way for the clinical success of
LTX which has finally become a standard therapy and
clinical routine.
Primary graft dysfunction after LTX is a critical event
and may display a broad clinical range from reversible
graft dysfunction, known as early allograft dysfunction
(EAD), up to an irreversible dysfunctional state called
primary non function which represents an indication for
urgent re-transplantation (Uemura et al. 2007). EAD has
been shown to have negative impact on both, patient and
graft outcome. Early and accurate assessment of graft
function following LTX is critical for timely therapeutic
intervention resulting in reduced mortality and reduced
numbers of re-transplantation. Moreover, sensitive and
specific assessment of the hepatic metabolism after LTX
remains essential for early detection of postoperative dys-
function and consecutive adjustment of the therapeutic
regime. In clinical routine, liver cell function is assessed by
the activity of in part specific enzymes such as alanine and
aspartate aminotransferase (ALT, AST), bilirubin and
parameters of the coagulation system such as the interna-
tional normalized ratio of prothrombin (INR) to define
EAD (Olthoff et al. 2010; Lee et al. 2014). Recently, a
model for the quantitative assessment of EAD after LTX
has been validated (model for early allograft function
scoring, MEAF) (Pareja et al. 2015). This score, based on
the parameters ALT, bilirubin and INR calculated at day 3
post-LTX, provides improved graft function assessment
than the single parameters (Pareja et al. 2015) while at the
same time being a predictor of both recipient and graft
survival. However, all single parameters used to calculate
the MEAF might be influenced by the ischemic period
during organ preservation, liver graft quality, coagulation
factor substitutions and blood or plasma transfusions, as
well as nutrition. Thus, evaluation of the actual parenchy-
mal function and precise distinction between a toxic and
hypoxic liver injury can be challenging (Hickman et al.
1997; Shaked et al. 1997; Tanaka et al. 2000; Sear 2002)
since routine parameters may rather reflect pre- and peri-
operative liver cell injury due to ischemia and organ
preservation than the residual metabolic capacity of the
transplanted liver.
To characterize new postoperative parameters that might
assess more adequately or even earlier EAD compared to
the MEAF, we here examined various liver specific
metabolic pathways including cholesterol synthesis and
secretion, sterol esterification, branched-chain and aro-
matic amino acids and fatty acid beta-oxidation by liquid
chromatography/tandem mass spectrometry (LC–MS/MS).
Free and esterified sterols, amino acids and acylcarnitines
were determined together with the routine parameters by
high throughput methods 1 day pre- and 10 days post-LTX
and related to clinical outcome and the MEAF.
The change of sterol concentrations before and after
LTX was studied in patients with end-stage primary biliary
cirrhosis and acute liver failure (Nikkila¨ et al.
1992, 2005, 2008). Here, we focused on sterol esterifica-
tion, which depends strongly on liver function and was
already discussed as a marker for it many years ago (Jones
et al. 1971; Simon et al. 1974). However, sterol esterifi-
cation has not been studied in liver function after trans-
plantation. Conversion of free sterols into sterol esters is
catalyzed by the lecithin cholesterol acyltransferase
(LCAT). This enzyme is synthesized in the liver and its
activity is a sensitive parameter of liver disease (Borowsky
et al. 1980; Breier et al. 1983). Using our LC–MS/MS
approach, we are able to determine sterol esterification by
simultaneous quantification of the free and esterified sterol
including cholesterol, endogenous andnon-endogenous sterols.
2 Materials and methods
2.1 Subjects
A total of 40 Caucasian men (n = 29) and women
(n = 11) undergoing LTX were consecutively recruited
from July 2008 to July 2009. Table 1 summarizes baseline
and hospitalization characteristics of patients pre-LTX. 27
out of the 40 patients (27/40) had alcoholic liver disease
(ALD) as baseline liver disease. 20/27 of these patients
were men. Alcohol abuse is a mostly problem of men: two-
thirds of people with alcohol use disorders are men
(Deleuran et al. 2015). We did not record the personalized
diet of each patient. The patients were fed according to the
following suggestions: (i) patients without any complica-
tion: post-LTX oral light diet, after 2–3 days stepwise
increasing caloric food; (ii) patients which could not be fed
orally within the first 1–4 days post-LTX but afterwards:
Ringer‘s solution i.v., after 4 days oral light diet and
increasing caloric food; patients with complications and
probably no oral nutrition after 4–5 days will be possible:
enteral nutrition according to the patients demand.
Three patients had to undergo re-transplantation after
their first LTX. Here, only the data after re-transplantation
were included. Two out of these three patients underwent a
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LTX 2 and 6 months before the second LTX because of
thrombosis of the liver artery. In both cases blood was not
collected after the first LTX. After the second LTX the
determined parameters of both patients were between the
25th and 75th percentile of all patients. The third patient
received the second LTX 4 days after the first LTX
because of acute liver failure. This is one of the patients
who died within 3 months after LTX.
2.2 Blood samples
1–24 h pre-LTX (day 0) and each day post-LTX until day
10 (days 1–10) peripheral venous blood was collected.
80.0 % of all blood samples were collected between 4 and
7 AM. and 9.1 % between 7 and 10 AM. Because all patients
were in the intensive care unit (ICU) post-LTX, taking
blood samples depended on the treatment needs. Thus, the
Table 1 Baseline and
hospitalization characteristics of
the patients pre-LTX
Parameter (unit) Number (%) Mean ± SD or
median (interquartile range)
Recipient information
Number of patients 40
Age (years) 53.68 ± 8.35
Gender (male) 29 (72.5)
Baseline liver disease
Alcoholic liver disease (ALD) 27 (67.5)
Hepatitis B/C 4 (10.0)
Hemochromatosis 2 (5.0)
Acute liver failure (ALF) 3 (7.5)
Posttransplant-liver complication 2 (5.0)
Biliar disease 2 (5.0)
Tumor (HCC) 13 (32.5)
MELD 19.50 (12.75–35.25)
MEAF 4.72 (3.25–6.11)
Transplantation before study transplantation 3 (7.3)
Mortality after 10 days 0 (0)
Mortality after 30 days 1 (2.5)
Mortality after 3 months 3 (7.5)
Organ failure after 30 days 2 (5.0)
Organ failure after 3 months 5 (12.5)
Organ failure after 18 months 8 (20.0)
Length of hospital stay (days) 30.50 (21–39.25)
Length of ICU stay (days) 13.00 (8.00–20.00)
Donor information
Age (years) donor 54.58 ± 17.59
Gender (male) donor 22 (55.0)
Gender mismatch
No 25 (62.5)
Male (D) ? female (R) 4 (10.0)
Female(D) ? male (R) 11 (27.5)
BMI (kg/m2) 26.18 (23.38–29.39)
Surgical information
CIT (min) 597 ± 146
Arterial anastomosis delay (min) 60.000 (50.00–60.00)
Mean and standard deviation (SD), for non-normally distributed parameters median and interquartile ranges
are given
BMI body mass index, CIT cold ischemic time, D donor, ICU intermediate care unit, HCC hepatocellular
carcinoma, MEAF model for early allograft function scoring, MELD model for end-stage liver disease,
R recipient
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remaining 10.9 % of blood samples could not have been
taken within the time frame 4–10 AM. The blood was
centrifuged immediately at 25009g for 20 min to obtain
EDTA-plasma. Samples were stored at -80 C and thawed
only once. To generate dried blood specimen, EDTA whole
blood was dropped on filter paper (grade 903; GE
Healthcare, Munich, Germany) dried at room temperature
for 3 h and afterward stored in foil-barrier ziploc bags and
desiccant packets (Whatman GmbH, Dassel, Germany) at –
80 C till analysis.
2.3 Scores
The model used for end-stage liver disease (MELD) score
was the crude MELD score. It was calculated with the
following formula after recruitment of the patients
(Kamath and Kim 2007): MELD = [0.957 ln(crea-
tinine) ? 0.378 ln(bilirubin) ? 1.120 ln(INR) ? 0.643] 9
10 (United Network for Organ Sharing, UNOS; MELD
Calculator; accessed March 30, 2015). MEAF was calcu-
lated with the following formula (Pareja et al. 2015) with
max3POD = maximum variable values during the first 3
postoperative days: MEAF = score ALTmax3POD ? score
INRmax3POD ? score bilirubin3POD. The MEAF could not
be determined for two patients. Clinical outcome as
3-month mortality (n = 3 patients), 3-month mortality/or-
gan failure (n = 5 patients), 12- and 18-month mortality
(n = 5 patients) were collected retrospectively.
2.4 Chemical and reagents
Methanol and isopropanol were purchased from Merck
(Darmstadt, Germany) and acetyl chloride (p.a.) from
Sigma-Aldrich (Steinheim, Germany). Water (HPLC
grade) was obtained from J. T. Baker (Deventer, Nether-
lands). AA and AC reference isotope labeled standard kits
(NSK A, NSK B; Cambridge Isotope Laboratories, And-
over, USA) were used as internal standard. 3N butanolic
HCl was made in-house using butanol (spectroscopy grade,
Merck Darmstadt, Germany). Dried blood controls for
amino acids and acylcarnitines (Level 1 and Level 2) were
obtained from Chromsystems (Munich, Germany).
2.5 Clinical laboratory characteristics
All analyzed parameters are summarized in Supplemental
Table 1. ALT and AST, gamma glutamyl transferase
(GGT), glutamate dehydrogenase (GLDH), creatinine and
bilirubin serum concentrations were analyzed using Cobas
6000 and 8000 analyzers (Roche, Mannheim, Germany).
The prothrombin assay was performed in citrate plasma to
determine the INR using an ACL TOP 700 System
(Instrumentation Laboratory, Lexington, USA).
2.6 LC–MS/MS analysis
Sterol analysis included the free and esterified plant sterols
brassicasterol (BR), campesterol (CA), b-sitosterol (SI) and
stigmasterol (ST), the cholesterol biosynthesis precursors
lanosterol (LA) as well as the sum parameter includ-
ing desmosterol, zymosterol, 7-dehydrocholesterol
(DEZY7DHC), and cholesterol itself (CH). They were
analyzed by LC–MS/MS (Lembcke et al. 2005; Becker
et al. 2015). 25 ll of the supernatants were injected onto
the analytical column (Chromolith SpeedROD RP-18e,
50 9 4.6 mm, monolithic column, Merck KGaA, Darm-
stadt, Germany). An API 4000 triple quadrupole mass
spectrometer with an atmospheric pressure photoionization
source (AB Sciex, Darmstadt, Germany) was used. The
quantification of free and esterified sterols was performed
according to ISO DIN 17025 and ISO DIN 15189 including
an external 4-point calibration with three quality controls at
different concentrations. Data were acquired using Analyst
software (version 1.5.1). The sterol esterification ratio was
calculated with the following formula: esterified sterol/
(free sterol ? esterified sterol) 9 100.
Analysis of amino acids and acylcarnitines was per-
formed according to published protocols (Ceglarek et al.
2002; Brauer et al. 2011). Briefly, 3 mm dried blood spots
were extracted with 100 ll of the internal standard solution
and centrifugated at 30009g for 10 min at room temper-
ature. After butanolic esterification, samples were analyzed
by liquid chromatography tandem mass spectrometry (API
2000, Sciex, Darmstadt, Germany).
2.7 Statistical analyzes
Before statistical analysis, non-normally distributed
parameters were logarithmically transformed to approxi-
mate normal distribution. Mean and standard deviation
(SD), for non-normally distributed parameters median and
the interquartile range (25th–75th percentile) were used.
All statistical computations were performed using SPSS
version 20.0 (IBM, Ehningen, Germany). p values less than
5 % were considered as significant.
Receiver Operating Characteristic (ROC) analyzes were
used to assess the diagnostic power of the new parameters
for discrimination between patients. The observed area
under the ROC curve (AUC) was tested against the null-
hypothesis (AUC = 0.5). Optimal cut-offs for the evalu-
ated parameters were derived from the ROC curves by
maximizing the sum of sensitivity and specificity (Youden-
Index).
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3 Results
Clinical and anthropometric characteristics of patients are
summarized in Table 1. The study group included 40 LTX
patients with a mean age of 53.7 ± 1.3 (35–69) years.
Alcoholic liver disease (ALD) was the predominant
underlying liver disease, followed by hepatitis B/C.
3.1 The esterification ratio of sterols showed
substantial disturbances pre- and post-LTX
Substantial metabolic disturbances occurred immediately
after LTX as seen in the time course of the esterification
ratio of all sterols (Fig. 1) and of routine parameters,
suitable to follow-up LTX, as ALT, AST, bilirubin, GGT,
glutamate dehydrogenase (GLDH), and prothrombin time
(PT). No or only low disturbances post-LTX were seen in
circulating amino acids as well as acylcarnitines (data not
shown).
The ratio of esterified sterols prior to LTX varied consid-
erably for each sterol among the patients (Fig. 1); e.g. of CA
between 11.8 and 83.9 %. Immediately post-LTX the esteri-
fication ratio of all sterols increased especially in patients with
a low esterification ratio pre-LTX. The esterification ratio of
all sterols post-LTX did not correlate to the cold ischemic
time of the donor liver (data not shown). At day 1 the ratio of
each esterified sterol, apart from ST, was higher than 50 % in
all patients. From day 2 post-LTX the ratio of esterified
sterols decreased continuously in at least half of the patients.
Thus, we included the difference in the ratio of esterified
sterols between day one to each other day after LTX into
further analysis. In part, the difference in the esterification
ratio between day 1 and 2 post-LTX was even more signifi-
cant. At day 10, the ratio of esterified sterols varied among the
patients partly as pre-LTX. For BR, CA and DEZY7DHC the
median esterification ratio was even higher pre-LTX com-
pared to that of day 10 post-LTX.
We found no significant differences between men and
women concerning age and all routine and sterol data.
Additionally, we found no differences between the 25 %
youngest and 25 % oldest women. Thus, it is likely that the
hormonal status/menopause had no effect on the results.
3.2 The esterification ratio of sterols correlates
inversely to the MEAF
Recently, the MEAF was identified to be most suitable for
modeling EAD in patients undergoing LTX (Pareja et al.
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Fig. 1 Time course of the ratio
of esterified sterols The median
and the 25 and 75 %
interquartile ranges (Q25/75)
are shown in red. The patients
who died within 3 months
(n = 3) and the patients with
organ failure (n = 2) are shown
in pink and in green,
respectively. The continuous
green line represents a patient
with EAD and high MEAF
whereas the green broken line
indicates a patient who lost the
liver 2 months post-LTX due to
thrombosis of the hepatic artery.
The differences between day 0
pre-LTX to each day post-LTX
are indicated (Wilcoxon signed-
rank test; *p\ 0.05,
**p\ 0.01, ***p\ 0.001)
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2015). The score includes ALT, bilirubin and INR. Con-
sequently, these parameters correlated to the MEAF (data
not shown). Interestingly, the esterification ratio of the
sterols correlated inversely to the MEAF almost every day
except day 1, i.e. the higher the MEAF the lower the
esterification ratio. The amount of free sterols and the
MEAF correlated slightly. Supplemental Fig. S1a shows
exemplarily that the data for free (SIF), esterified (SIE),
total (SIT), and the ratio of esterified SI (SIE %) correlated
to ALT, bilirubin, INR and MEAF whereas figure S1b
illustrates the correlation between the esterification ratio of
each sterol to the MEAF at days 3, 6, and 9 post-LTX.
Finally receiver operating characteristic (ROC) analysis
was performed. As binary classifier the 75 % percentile of
the MEAF, e.g. the 25 % of the patients with a
MEAF C 6.10 were compared to the others. The low
esterification ratio from day 1 of SI and ST and from day 3
of all the other sterols was predictive for a high MEAF
(Fig. 2). Thus, high ratios of circulating esterified sterols
probably predict a low risk of EAD. The Youden-Index,
defining the maximum potential effectiveness and the cut-
off of the esterification ratio, was calculated (Fig. 2). The
highest Youden-Index was 0.82 for SIE % at day 2 post-
LTX (cut-off 59.10 %) and 0.90 for CHE % at day 5 post-
LTX (cut-off 57.80 %).
The other non-routine parameters such as amino acids
and acylcarnitines either did not correlate or randomly
correlated to the MEAF and are thus not predictive
(Fig. S2).
3.3 The ratio of esterified sterols predicts clinical
outcome
Finally, we evaluated the prognostic value of the assessed
metabolic parameters on clinical outcome. Patients who
died within the first three months after LTX very often
showed esterification ratios of the sterols below the median
of all patients or even the lowest values on many days
(Fig. 1). The two patients who lost the organ had different
profiles: the one with EAD was comparable to patients who
died within 3 months whereas the patient who lost the liver
2 months post-LTX due to thrombosis of the hepatic artery
with no signs of EAD and a low MEAF always had high
esterification ratios of the sterols (Fig. 1). In the ROC
classification 75. percentile MEAF 75. percentile MEAF 75. percentile MEAF
xednI-neduoYeulav-pCUA
patients (n) 38 38 38 38 38 38 37 36 32 29 38 38 38 38 38 38 37 36 32 29 38 38 38 38 38 38 37 36 32 29
patients group 1 (n) 9 9 9 9 9 9 9 9 8 6 9 9 9 9 9 9 9 9 8 6 9 9 9 9 9 9 9 9 8 6
day post-LTX 1 2 3 4 5 6 7 8 9 10 1 2 3 4 5 6 7 8 9 10 1 2 3 4 5 6 7 8 9 10
routine
ALT
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GLDH
PT
sterols
BRF
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BRT
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DEZY7DHCE
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DEZY7DHCE%
ΔDEZY7DHCE%
LAF
SIF
SIE
SIT
SIE%
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STF
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Fig. 2 Sterols as predictors for
a high MEAF receiver operating
characteristic (ROC) analysis to
verify which parameter predicts
a high MEAF. The 75 %
percentile of the MEAF was
used as binary classifier, i.e. the
25 % of the patients with a
MEAF C 6.10 were compared
to the others. Values for the area
under the curve (AUC; 0–1),
p values (\0.05–0) and the
Youden-Index (0–1) are shown
in heat maps. The Youden-
Index, defining the maximum
potential effectiveness of the
parameter, was calculated from
the AUC curves
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analysis 3, 12, and 18 month mortality were used as binary
classifiers. In Fig. 3, the AUC and the level of significance
for 3-month mortality are given for each day. Among the
routine parameters, bilirubin and GLDH were predictive on
nearly all days as was the MEAF determined at day 3.
Among the newly evaluated parameters, the sterols were
especially interesting. Free LA (LAF), free ST (STF) and
free and the ratio of esterified SI (SIF, SIE %) were pre-
dictive on all days post-LTX. The ratio of esterified as well
as difference in the ratio of esterified BR (BRE, DBRE %)
and CA (CAE, DCAE %) were predictive from day 3 post-
LTX. For 12, and 18 month mortality the same results
tended to be seen as for 3-month mortality, albeit at a lower
or no level of significance. Finally, the Youden-Index was
calculated (Fig. 3). The highest Youden-Index was 0.95 for
SIE % (cut-off 57.52 %) and 1.00 for LAF at day 2 post-
LTX (cut-off 0.27 mg/l) which are better than that of the
MEAF calculated at day 3 post-LTX.
Circulating amino acids were not informative (Fig. S3).
In tendency, several short- and medium-chain acylcarniti-
nes showed predictive AUC levels, but they never or only
on single days reached the level of significance.
4 Discussion
Here, we identified a significant predictive value for the
esterification ratio of circulating sterols on EAD and
3-month mortality in patients undergoing LTX.
Circulating sterols are composed of cholesterol, an
essential component of membranes by regulating the flu-
idity of the bilayer, several precursors of cholesterol as
lanosterol which are markers for cholesterol synthesis, and
plant sterols which are exclusively derived from dietary
sources (Kuksis 2001). Intracellular esterification and the
subsequent packing into cytoplasmic lipid droplets detox-
ifies and sequesters sterols until they are required. The
hydrophobic sterols are transported in circulation via
lipoproteins to the peripheral cells (Huang et al. 2015).
The esterification ratio of sterols depends on two
enzymes. Sterol esterification for synthesis of chylomi-
crons and very low-density lipoproteins (VLDLs) to
transport synthesized sterols from the liver in the circula-
tion is catalyzed by acyl-coenzyme A: cholesterol acyl-
transferase 2 (ACAT2) (Rogers et al. 2015). The LCAT,
secreted by the liver into the blood, influences sterol
classification 3- months mortality
xednI-neduoYeulav-pCUA
patients (n) 40 40 40 40 40 40 39 38 33 30 40 40 40 40 40 40 39 38 33 30 40 40 40 40 40 40 39 38 33 30
patients group 1 (n) 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
day post-LTX 1 2 3 4 5 6 7 8 9 10 1 2 3 4 5 6 7 8 9 10 1 2 3 4 5 6 7 8 9 10
routine
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DEZY7DHCF
DEZY7DHCE
DEZY7DHCT
DEZY7DHCE%
ΔDEZY7DHCE%
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SIE
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3- months mortality 3- months mortalityFig. 3 Sterols as predictors for
3 month mortality Receiver
operating characteristic (ROC)
analyzes to verify which
parameter predicts clinical
outcome. 3 month mortality was
used as binary classifier.
Explanations see Fig. 2
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esterification in circulating lipoproteins (Glomset and
Verdery 1977; Dobiasova and Frohlich 1999; Jonas 2000).
LCAT activity itself is a sensitive parameter for the
severity of the liver disease (Borowsky et al. 1980; Breier
et al. 1983). Thus, the esterification ratio of circulating
sterols correlates to the number of intact hepatocytes.
Overall, the plasma concentration of LCAT in normal liver
function showed only minor variation (Kunnen and Van
2012) and varied only slightly in adult humans with age,
gender, and smoking (Albers et al. 1982).
In our study, the ratio of each esterified sterol was sig-
nificantly different between the patients pre-LTX with
variances around 50–70 %. Of note was the marked
increase in the esterification ratio immediately post-LTX
for all sterols in patients that had shown low esterification
ratios pre-LTX. From day two post-LTX the esterification
ratio of all sterols started decreasing in more than 50 % of
the patients. This uniform time course for all sterols sug-
gests either that during LTX highly esterified sterols, typ-
ical for healthy individuals (Temel et al. 2003) have been
transfused or that the LCAT activity of the donor liver is
not disturbed immediately after LTX. Consistently, the
ratio of all esterified sterols correlated strongly to routine
parameters defining EAD and variables of the MEAF
(Olthoff et al. 2010; Lee et al. 2014; Pareja et al. 2015).
The low esterification ratio of SI and ST from day 1 and of
the other sterols from day 3 was predictive to be among the
25 % of the patients with the highest MEAF. Although
based on a small study cohort, these data suggest that the
low esterification ratio of sterols is predictive for EAD.
Circulating plant sterols such as BR, CA, SI and ST
solely result from dietary intake (Gylling et al. 2014; Ikeda
2015) and cannot be metabolized in the human organism
except by being esterified predominantly in the liver
(Chang et al. 2006). In our study, the esterification ratio of
SI from day 1 and of BR and CA from day 3 as well as the
difference in the esterification ratio day 1–2 of ST pre-
dicted a 3-month mortality after LTX. Interestingly, the
free form of SI and ST was also predictive for a 3-month
mortality from day 1 until day 10 post-LTX. The same
association could be found for free LA. LA is a non-CH
sterols that are active precursors in the cellular CH
biosynthesis. Their CH-normalized concentrations are
surrogate markers reflecting endogenous de novo synthesis
of CH in the liver (Miettinen et al. 1990). The fact that free
LA, SI, ST also predict 3-month mortality suggests that
disturbances in hepatic cholesterol synthesis and choles-
terol efflux by biliary excretion impact cholesterol
homeostasis.
In addition, we also evaluated whether systemic levels
of circulating amino acids were predictive for EAD and
clinical outcome post-LTX. Altered amino acid metabo-
lism is a hallmark of liver disease. Acute liver failure
(ALF) is characterized by elevated levels of the circulating
aromatic amino acids (AAAs) Phe, Trp and Tyr as well as
Met. In contrast, reports on the concentrations of circulat-
ing branched-chain amino acids (BCAAs) Leu/Iso and Val
have been conflicting (Blonde-Cynober et al. 1999; Honda
et al. 2004). In chronic liver failure (CLF), decreased cir-
culating BCAA and slightly elevated AAAs concentration
have been reported consistently (Fischer et al. 1976;
Watanabe et al. 1982). In the present study, the circulating
level of all amino acids and the Fisher ratio, i.e. the ratio of
the BCAAs to AAAs, did not correlate to the MEAF. Of
note was the prediction of mortality for some amino acids
and of organ failure only on day 1 after LTX which might
be caused by blood transfusion or nutritional effects linked
to caloric substitution. Overall, the patients with an unfa-
vorable time course post-LTX received a different nutri-
tional regimen compared to the patients with an
uncomplicated healing. Probably the different scheme in
nutrition explains the missing correlation between liver
function and plasma amino acids and acylcarnitines.
However, sterol esterification is not influenced by nutrition.
Finally, we also examined the carnitine shuttle and beta-
oxidation of fatty acids. L-carnitine transports fatty acids
into the mitochondria for subsequent b-oxidation, a process
which results in its esterification to form acylcarnitine
derivatives. As such, the endogenous carnitine pool is
comprised of L-carnitine and various short-, medium- and
long-chain acylcarnitines (McCoin et al. 2015). Thus,
acylcarnitines play a decisive role in free fatty acid (FFA)
oxidation, responsible for the transportation of acyl-coen-
zyme A into mitochondria, especially in liver and muscle
cells. Acute liver failure with microvesicular steatosis is
the consequence of severe impairment of mitochondrial
beta-oxidation (Pessayre et al. 1999; Jaeschke et al. 2002).
However, we did not find any correlation between L-car-
nitine/acyl carnitines and any of the routine parameters
defining EAD and the MEAF. Long-chain acyl carnitines
are sensitive biomarkers of acetaminophen (APAP)-in-
duced hepatotoxicity in mouse models and human children
(Bhattacharyya et al. 2013, 2014). High doses of APAP, the
most widely used drug for the treatment of pain and fever,
is the major cause of acute liver failure (ALF). In our study,
none of the patients with acute liver failure had abused.
Long-chain acylcarnitines accumulated, whereas free car-
nitine, medium and short-chain acylcarnitines decreased
with the severity of the non-malignant chronic liver dis-
eases, accompanied with corresponding alterations in
enzyme activities of carnitine palmitoyl transferase 2
(CPT2) (Zhou et al. 2012).
In summary, we present promising data showing that
sterols and especially their esterification ratios are suit-
able markers to follow up LTX and to predict EAD and
clinical outcome. Our results clearly indicate the diagnostic
182 Page 8 of 10 U. Ceglarek et al.
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potential of circulating sterols in the context of liver
function assessment and justify further in-depth
exploration.
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